Stockhead on MSN1h
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure
One of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...
Opthea’s flagship clinical trial has failed, with the biotech’s solvency now on the line
Biotechnology firm Opthea has warned investors its solvency is in question after the failure of a major clinical trial into ...
Ophthalmology Times4d
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
The investigators retrospectively evaluated 126 consecutive treatment-naïve nAMD patients (126 eyes) who received a loading ...
JD Supra5d
Federal Circuit Affirms Denial of Injunction Against Amgen in Aflibercept BPCIA Litigation
On March 14, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West Virginia’s ...
Fintel on MSN5d
RBC Capital Initiates Coverage of Ocular Therapeutix (OCUL) with Outperform Recommendation
Fintel reports that on March 18, 2025, RBC Capital initiated coverage of Ocular Therapeutix (NasdaqGM:OCUL) with a Outperform ...
It’s Phil King’s Regal against the shorts at biotech play Opthea
The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial ...
Trading in Opthea Halted Ahead of Update on Wet AMD Study
Trading in shares of Opthea is halted in the U.S. and Australia ahead of planned update by the clinical-stage biopharmaceutical company on a late-stage study of its lead product candidate ...
TipRanks on MSN5d
Opthea Limited Suspends Trading Pending Clinical Trial Results
Opthea Limited ( ($AU:OPT) ) has shared an update. Opthea Limited has requested a voluntary suspension of its securities from trading on the ASX ...
pharmaphorum2d
Oxurion files for bankruptcy as DME drug fails
The KALAHARI study compared intravitreal injections of THR-149 to Regeneron and Bayer’s anti-VEGF antibody Eylea (aflibercept), a widely-used therapy for DME, in 112 patients for whom the ...
pharmaphorum3d
Novartis halts three trials of Beovu eye drug on safety concerns
but that was offset by higher rates of inflammatory reactions in the eyes – some of which could be sight threatening – compared to rival anti-VEGF therapy Eylea (aflibercept) from Bayer and ...